Technology · 16/10/2026
AMCP Market Insights Findings Show Uncertainty in Biomarker Testing for ESR1-Mutated Advanced Breast Cancer as Payers Weigh Earlier Detection and a Growing Class of Targeted Therapies
The American College of Clinical Pharmacology (AMCP) has released findings on biomarker testing for ESR1-mutated advanced breast cancer, highlighting uncertainty among payers regarding earlier detection and targeted therapies.